| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 57.27 0.67 (1.18%) | 06-05 16:00 | ||
| Open: | 57.03 | Pre. Close: | 56.6 |
| High: | 57.815 | Low: | 56.79 |
| Volume: | 9,516,350 | Market Cap: | 116,949(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 70.37 One year: 82.19 |
| Support: | Support1: 56.51 Support2: 54.20 |
| Resistance: | Resistance1: 60.25 Resistance2: 70.37 |
| Pivot: | 57.19 |
| Moving Averages: | MA(5): 55.60 MA(20): 56.96 MA(100): 58.01 MA(250): 51.04 |
| MACD: | MACD(12,26): -0.49 Signal(12,26,9): -0.40  |
| %K %D: | %K(14,3): 33.00 %D(3): 18.76 |
| RSI: | RSI(14): 50.58 |
| 52-Week: | High: 62.89 Low: 42.52 Change(%): 24.2 |
| Average Vol(K): | 3-Month: 11091 10-Days: 10175 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 57.897 - 58.13 | 58.13 - 58.371 |
| Low: | 56.216 - 56.459 | 56.459 - 56.709 |
| Close: | 56.873 - 57.293 | 57.293 - 57.726 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BMY ] has closed below upper band by 48.6%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
Sat, 06 Jun 2026 Sat, 06 Jun 2026 Sat, 06 Jun 2026 Sat, 06 Jun 2026 Sat, 06 Jun 2026 Sat, 06 Jun 2026 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2040.00 |
| Shares Float (M) | 2040.00 |
| % Held by Insiders | 0.08 |
| % Held by Institutions | 83.71 |
| Shares Short (K) | 36720 |
| Shares Short Prior Month (K) | 32390 |
| Stock Financials | |
|---|---|
| EPS | 3.570 |
| Book Value (p.s.) | 9.830 |
| Profit Margin | 15.01 |
| Operating Margin | 33.04 |
| Return on Assets (ttm) | 10.7 |
| Return on Equity (ttm) | 38.7 |
| Qtrly Rev. Growth | 2.6 |
| Gross Profit (p.s.) | 17.108 |
| Sales Per Share | 23.765 |
| EBITDA (p.s.) | 9.299 |
| Qtrly Earnings Growth | 9.20 |
| Operating Cash Flow (M) | 13310.00 |
| Levered Free Cash Flow (M) | 9850.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 16.04 |
| PEG Ratio | 180.38 |
| Price to Book value | 5.83 |
| Price to Sales | 2.41 |
| Price to Cash Flow | 8.78 |
| Stock Dividends | |
|---|---|
| Dividend | 0.630 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
